Synchrogenix a Certara company Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Synchrogenix a Certara company's estimated annual revenue is currently $49.4M per year.(i)
  • Synchrogenix a Certara company's estimated revenue per employee is $201,000

Employee Data

  • Synchrogenix a Certara company has 246 Employees.(i)
  • Synchrogenix a Certara company grew their employee count by -10% last year.

Synchrogenix a Certara company's People

NameTitleEmail/Phone
1
VP, Global Submissions and Submissions LeadershipReveal Email/Phone
2
VP, Regulatory Science and Medical AffairsReveal Email/Phone
3
Associate Director, Regulatory ServicesReveal Email/Phone
4
Director, Medical Publications and CommunicationsReveal Email/Phone
5
Senior Director, Commercial OperationsReveal Email/Phone
6
Director, Global SubmissionsReveal Email/Phone
7
Director, Global SubmissionsReveal Email/Phone
8
Senior Director, Transparency & DisclosureReveal Email/Phone
9
Director Clinical WritingReveal Email/Phone
10
Director, Nonclinical/CMC Regulatory WritingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$34M1698%N/AN/A
#2
$8.4M42-28%N/AN/A
#3
$68.7M3426%N/AN/A
#4
$49.4M246-10%N/AN/A
#5
$7.8M3944%N/AN/A
#6
$148.3M7388%N/AN/A
#7
$24.7M12313%N/AN/A
#8
$0.8M814%N/AN/A
#9
$9M457%N/AN/A
#10
$3.8M19-50%N/AN/A
Add Company

What Is Synchrogenix a Certara company?

PROVIDING REGULATORY STRATEGY, SCIENCE, and SERVICES to PHARMACEUTICAL, DEVICE/DIAGNOSTICS, and TOBACCO COMPANIES WORLDWIDE REGULATORY STRATEGY - Strategic cross-functional guidance and comprehensive implementation - Submission and Program Leadership - Strategic messaging alignment, overall Vendor strategy and management, agency communications - Modules 1-5 of the Common Technical Document (CTD) / PMA, 510k / PMTA, TPMF, MRTP - Regulatory Operations REGULATORY and MEDICAL WRITING By merging our cross-functional expertise with our writing and operations experience, we deliver documents that not only support clients strategic messaging, but also enhance their marketability. We provide many of the benefits of an in-house teamincluding the experience and perspective of industry insiderswithout increased overhead or struggles with fluctuating workloads. Synchrogenix provides clients with objective, professional document review services. Our rigorous quality-control process includes checks of data, formatting, spelling, grammar, and clarity. Our team includes industry experts, medical doctors, and clinicians who provide our clients with objective content review. TECHNOLOGY-ENABLED SERVICES - GlobalSubmit Regulatory operations technology - ClinGenuity Artificial intelligence technology platform TRANSPARENCY and DISCLOSURE Our disclosure team consults with our clients to educate cross-functional teams as to the requirements for and compliance to FDAAA, FDAMA, and EMA's policies 43 and 70. We develop a roadmap for compliance for our domain experts to fulfill in tandem with client stakeholders. - Global Trial and Results Registries - Redaction and Dataset De-Identification - Plain Language Summaries, in partnership with CISCRP

keywords:Biotechnology,Healthcare,Pharmaceuticals

N/A

Total Funding

246

Number of Employees

$49.4M

Revenue (est)

-10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Synchrogenix a Certara company News

2022-02-22 - Certara's Synchrogenix Division Provides Unique Technology ...

PRINCETON, N.J.--(BUSINESS WIRE)--Certara®, the global biosimulation technology-enabled drug development company, today announced that its...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$49.4M2466%N/A
#2
$90.9M2528%N/A
#3
N/A25522%N/A
#4
$81.7M2567%N/A
#5
$51.3M2599%N/A